146 results
424B5
TPST
Tempest Therapeutics Inc
20 Jun 24
Prospectus supplement for primary offering
8:32am
of patients with HCC.
Manageable Safety Profile: The safety profile of amezalpat was manageable and consistent with its mechanism of action and data … observed in Phase 1 trials, suggesting a controllable safety profile heading into a pivotal Phase 3 trial.
Notable New Complete Response: A late
8-K
EX-1.1
TPST
Tempest Therapeutics Inc
20 Jun 24
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
8:13am
seq.); (iv) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
20 Jun 24
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
8:13am
safety profile consistent with Phase 1 data
The earlier top-line data analysis, dated April 20, 2023, had a median follow up of 9.2 and 9.9 months … arm in PD-L1 negative tumors
amezalpat remains well tolerated, with safety data comparable between the two arms
The randomized arms were generally
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
9 May 24
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
4:25pm
: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower
8-K
EX-99.1
4w8nuniz2wl aed0up1z
19 Mar 24
Tempest Reports Year End 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
lcbqwjng
8 Nov 23
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
5:18pm
8-K
EX-99.1
gch o8mig
11 Oct 23
Entry into a Material Definitive Agreement
8:13am
8-K
EX-99.1
65jjxcdu cyg9ajbt1r
10 Aug 23
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
4:27pm
8-K
EX-99.1
sgzqc9q3plwhnsah
10 May 23
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
4:21pm
8-K
EX-99.1
f63h5
28 Apr 23
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
8:30am
8-K
EX-99.1
1m1hladclqkc dv
9 Jun 22
Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance
8:08am
8-K
EX-99.1
mdicq xwtgw
26 May 22
Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting
5:06pm